PACED-digitized Support During Adjuvant Endocrine Therapy
NCT ID: NCT05084625
Last Updated: 2024-04-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
300 participants
INTERVENTIONAL
2021-10-25
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Innovative Smartphone Application for Adverse Event Management During Breast Cancer Adjuvant Chemotherapy
NCT05258461
Digital Patient Support Program for Self-efficacy and Medication Adherence in Women on Adjuvant Endocrine Treatment for Breast Cancer
NCT06989450
Impact of Web Application Support Versus Standard Management on Compliance With Adjuvant Hormone Therapy at 18 Months in Patients Treated for Breast Cancer
NCT04554927
Expectations and Side Effects of Endocrine Therapy in Women With Breast Cancer
NCT02088710
Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer
NCT00022516
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A- access to digitized support, an app
Patients in Arm A will have access to digitized support-an app for 12 months from baseline in addition to standard follow-up.
Digitized support
Access to information about the disease, treatment, side effects and self-care
Arm B-standard follow-up
Patients in Arm B-will continue with standard follow-up from baseline and onwards
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Digitized support
Access to information about the disease, treatment, side effects and self-care
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* On adjuvant endocrine treatment 0-16 weeks ago
Exclusion Criteria
* No access to a mobile phone or internet
* Not understanding Swedish
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ScientificMed Tech AB
UNKNOWN
AstraZeneca
INDUSTRY
Novartis Sverige AB
UNKNOWN
Bröstcancerförbundet
UNKNOWN
Stockholm South General Hospital
OTHER
Capio St Gorans hospital
UNKNOWN
Karolinska University Hospital
OTHER
Region Stockholm
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jenny Bergqvist
Role: PRINCIPAL_INVESTIGATOR
St Gorans Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Karolinska University Hospital
Stockholm, , Sweden
Oncology department Capio St Gorans Hospital
Stockholm, , Sweden
Södersjukhuset
Stockholm, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jenny Bergqvist
Role: primary
Anna Larsson-Wrake
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-02902
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.